Saturday 17 October 2026
Export UNCY’s income statement to Excel — free account
Unicycive Therapeutics, Inc.
UNCY Healthcare Biotechnology
Unicycive Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $675,000.00, down 29.0% from fiscal 2022. In the quarter to June 2026, EPS grew 88.5% and free cash flow grew 9.77%, each against the same quarter a year earlier.
3.36
0.23
−6.41%
Follow UNCY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.28 | 2.06 | 2.18 | 3.25 | |
Current Ratio |
3.81 | 2.40 | 2.59 | 3.83 | |
Net Debt/EBITDA |
6.13 | 6.65 | 5.84 | 5.93 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
4.42 | 0.49 | 0.55 | 0.99 | |
Capex/Depreciation |
0.01 | (0.04) | 0.00 | (0.01) | |
Interest Coverage |
— | — | (257.96) | (489.47) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.28) | (0.26) | (0.51) | (0.33) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.28) | (0.26) | (0.51) | (0.33) | |
Cash per Share |
2.28 | 2.28 | 2.60 | 2.36 | |
Shareholders Equity per Share |
1.98 | 1.58 | 1.90 | 2.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.98 | 1.58 | 1.90 | 2.07 | |
Free Cash Flow |
(7.60) | (6.25) | (8.03) | (5.96) | |
Working Capital |
52.62 | 37.06 | 30.02 | 37.16 | |
Capital Expenditures |
0.00 | (0.01) | 0.00 | 0.00 | |
Net Current Asset Value |
52.56 | 36.84 | 30.02 | 37.16 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
1.50 | 1.27 | 0.72 | 0.75 | |
Average Assets |
51.01 | 46.18 | 40.40 | 44.59 | |
Average Common Equity |
34.85 | 24.49 | 18.81 | 32.67 |
Columns are period end dates